Renal Cell Carcinoma News and Research RSS Feed - Renal Cell Carcinoma News and Research

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.
Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology. [More]
Duke researchers identify promising target for renal cell carcinomas

Duke researchers identify promising target for renal cell carcinomas

All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread. [More]
Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics. [More]
PD-L1 inhibition well-tolerated, active in metastatic RCC

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings. [More]
CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine. [More]
HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, today announced it has opened a new fund to provide financial assistance to Medicare patients suffering from renal cell carcinoma (RCC). [More]
Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. [More]
Rutgers research reveals mechanism to prevent benign kidney tumor from becoming cancerous

Rutgers research reveals mechanism to prevent benign kidney tumor from becoming cancerous

Research from investigators at Rutgers Cancer Institute of New Jersey examining the inner workings of a rare non-cancerous (benign) kidney tumor has revealed a mechanism to prevent this type of tumor from becoming cancerous (malignant). [More]
Meat-rich diet may increase kidney cancer risk

Meat-rich diet may increase kidney cancer risk

A new study indicates that a meat-rich diet may increase the risk of developing kidney cancer through mechanisms related to particular cooking compounds. Also, these associations may be modified by genetic susceptibility to kidney cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study illustrates how diet and genetics may interact to impact cancer risk. [More]
Brain metastases evolve ‘clinically actionable’ mutations

Brain metastases evolve ‘clinically actionable’ mutations

Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far. [More]

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria. [More]
New drug works better than current treatments for advanced kidney cancer

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute. [More]
Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine. [More]
Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer. [More]
Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited. [More]
CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy. [More]
Active surveillance ‘viable option’ for SRM management

Active surveillance ‘viable option’ for SRM management

US researchers find no significant difference in survival outcomes between patients with small renal masses who opt for active surveillance and those who choose immediate treatment. [More]
Tolerability benefits with sunitinib schedule switch

Tolerability benefits with sunitinib schedule switch

Switching sunitinib treatment from a 4/2 to a modified 2/1 schedule can improve the tolerability profile for patients with metastatic renal cell carcinoma, say researchers. [More]
First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study. [More]
Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney. [More]
Advertisement